FibroGen
Dana Fong has a diverse work experience in the field of IT and software development. Dana most recently worked at FibroGen, Inc. as the Director of IT Business Integrations. Prior to that, they were an IT consultant at LinkedIn and held the position of Senior Software Architect at Gilead Sciences. Dana also has experience working as a consultant at various other companies including Genentech, Chiron Corporation, Johnson & Johnson, Incyte Genomics, and Oracle Corporation. Throughout their career, Dana has been involved in various responsibilities such as developing web applications, leading technology implementations, managing teams, and optimizing database procedures.
Dana Fong obtained a Bachelor of Arts (B.A.) degree in Applied Mathematics from the University of California, Berkeley. No specific information is provided regarding the years of study or any other educational experiences.
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.